Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Islet Function in Gestational Diabetes
NCT07806695Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Sep 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
Phase 1, open-label trial of exendin 9-39 in gestational diabetes mellitus (GDM) (2 arms), sponsored by Mayo Clinic. Primary endpoint: G50. Started Sep 2026; status: recruiting.
02
Drugs
exendin 9-39
03
Conditions
gestational diabetes mellitus (GDM)
Beyond the preview
Go deeper on NCT07806695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07806695.